eMedicine Specialties > Psychiatry > Adult

Schizophrenia: Follow-up

Author: Frances R Frankenburg, MD, Associate Professor, Department of Psychiatry, Boston University School of Medicine; Chief of Inpatient Psychiatry and Consulting Psychiatrist, Edith Nourse Rogers Memorial Veterans Administration Medical Center; Associate Psychiatrist, McLean Hospital
Contributor Information and Disclosures

Updated: Sep 10, 2009

Follow-up

Further Inpatient Care

  • Inpatient hospitalizations are caused by an exacerbation of symptoms, due to medication noncompliance, substance abuse, medication adverse effects or toxicity, medical illness, psychosocial stress, or the waxing and waning of the illness itself.
  • Admission to the hospital is stressful for anyone, but for someone with schizophrenia, who can find change difficult and who is suffering an exacerbation of his or her symptoms, it can be particularly frightening. The role of the nurse is important in helping to assess the cause for the hospitalization; monitoring response to therapy; and providing support, reassurance, and encouragement.
  • Hospitalizations are usually brief and for the purposes of crisis management or symptom stabilization.
  • Some patients are so disorganized because of their symptoms that they are unable to live in the community and live on long term inpatient units. These units are usually found in state hospitals or Veterans Administration hospitals, and are becoming increasingly rare.

Further Outpatient Care

  • The bulk of care for patients with schizophrenia occurs in an outpatient setting. This probably is best carried out by a multidisciplinary team. Suggested members of the team include a psychopharmacologist, counselor or therapist, social worker, nurse, vocational counselor, and case manager. Clinical pharmacists and internists can be valuable members.
  • Treatment requires an integration of medical, psychological, and psychosocial inputs.
  • In the United States, many people with schizophrenia do not live with their families. They do not always have the skills needed for independent living, so a system of alternative housing arrangements has emerged. At their most basic, these systems may consist of boarding houses or single-room occupancy (SRO) hotels with no supervision. Many organizations, often state-supported, provide communal-living settings with 24-hour supervision in halfway houses. Veterans Administration (VA) facilities have developed a sophisticated system of family care homes. Therapeutic halfway houses in which independence and social skills training are encouraged also exist.
  • One form of case management known as assertive case treatment is typically used for patients who have had multiple inpatient hospitalizations. The treatment involves active outreach to patients. Case managers usually have a fairly small outpatient load of about 10 patients and are able to go into the community to work with their clients. The managers coordinate and integrate care. The case managers, who may come from various disciplines, identify indications for treatment, make referrals to appropriate services, and promote engagement with interventions. This kind of treatment is very expensive but may be associated with a better clinical and social outcome and decrease in hospitalization.

Deterrence/Prevention

In studies in Norway and North America, researchers have found preliminary evidence that treatment of the prodrome of schizophrenia (the subclinical phase that is a precursor to acute psychosis) may delay onset of psychosis or reduce the severity of the illness.26

Complications

  • Alcohol and drug abuse are common. Of patients with schizophrenia, 20-70% have a comorbid substance abuse problem. Comorbid substance abuse, particularly common in younger men, is associated with increased hostility, crime, violence, suicidality, noncompliance with medication, homelessness, poor nutrition, and poverty. Patients who abuse substances may fare better in dual diagnosis treatment programs, in which principles from both mental health and chemical dependency fields can be integrated.
  • Noncompliance with medication is difficult to estimate but is common, and it is one of the reasons for the use of intramuscular (IM) preparations of antipsychotic medications. A regular routine of IM medication is preferred by some patients, and it is easier for the clinician to monitor medication adherence when IM medication is used.
  • Family and treaters should encourage the person to take their medication, while at the same time respecting his or her autonomy. This is a difficult balance to achieve.
  • Many patients with schizophrenia report symptoms of depression. Considerable uncertainty exists as to whether depression is part of schizophrenia, a reaction to the illness, or a complication of treatment. This is a particularly important problem because of the high rate of suicide in patients with schizophrenia. The research evidence for the use of antidepressant agents in schizophrenia is mixed. Further complicating the situation are the findings that antipsychotic agents, even the older conventional agents, may have antidepressant properties.27
  • Some patients may be violent, sometimes due to hallucinations or delusions.
    • Because the violence may be unpredictable and bizarre, these events are often highly publicized. An unfortunate consequence is the exacerbation of stigma.
    • Violence may be associated with command hallucinations or substance abuse.28
    • Most patients are not violent and are usually afraid of others rather than threatening to others. The rate of violence in patients with schizophrenia who do not abuse substances is about the same as in people without schizophrenia.

Prognosis

The prognosis of schizophrenia is guarded.

  • Patients with schizophrenia have a 10% risk of suicide.
  • Full recovery is unusual.
  • Symptoms usually follow a waxing and waning course.
    • The patient's pattern of symptoms may change over years.
    • Positive symptoms respond fairly well to antipsychotic medication, but the other symptoms are quite persistent.
  • Early onset of illness, family history of schizophrenia, structural brain abnormalities, and prominent cognitive symptoms are associated with poor prognosis.
  • This illness is little understood, and the available treatment is unacceptably poor. Research is ongoing into the pathophysiology and treatment of this illness. With earlier intervention with improved agents the goal is complete resolution of all symptoms of this illness and continuation or resumption of a full meaningful life.

Patient Education

  • Because of the nature of schizophrenia, the patients may have difficulty understanding the illness. Nevertheless, teaching the patient to understand the importance of medication compliance and abstinence from alcohol and other drugs of abuse is important.
  • Working with the patient so that patient and treatment team (and perhaps family members) can learn to recognize early signs of a decompensation, such as insomnia or increased irritability, is helpful.
  • Family members should be referred to the National Alliance on Mental Illness (NAMI) (or other appropriate support group if available), which provides many educational opportunities.
  • Social skills training is helpful, but the effects are not long-lived. This kind of training, as well as other sorts of problem-solving therapy, may need to be continued on an indefinite basis, similar to the medication.
  • Physical illnesses in schizophrenia are common. The importance of a healthy lifestyle and regular health care should be stressed.
  • For excellent patient education resources, visit eMedicine's Mental Health and Behavior Center. Also, see eMedicine's patient education article Schizophrenia.
  • Other helpful resources are available here:

Miscellaneous

Medicolegal Pitfalls

  • Misdiagnosis is a pitfall. Treatable illnesses, such as Wilson disease, endocrine dysfunction, or infectious illnesses, are particularly important to diagnose.
  • Physicians should warn people being treated with conventional antipsychotic agents about the risk of tardive dyskinesia. Regular examinations, using the abnormal involuntary movement scale (AIMS), should be performed to document its presence or absence.
  • Do not neglect the medical care of the person with schizophrenia. Obesity, diabetes, cardiovascular disease, and lung diseases are prevalent in schizophrenia, and the person with schizophrenia often does not get adequate medical care.29
  • Children, pregnant or breastfeeding women, and elderly patients present special challenges. In all of these cases, use medications with particular caution.

Special Concerns

  • Poverty: Because of vocational difficulties, many patients with schizophrenia also have to cope with the burdens of poverty.
  • Health insurance: In the United States, patients who do not work may be eligible for governmental programs, such as Medicare and Medicaid. These programs pay the cost of medical care. Unfortunately, once persons begin to work and earn a sufficient salary, they are at risk of losing these benefits. This is particularly awkward because they may be working in a setting with minimal or no health benefits. This situation is complicated and must be monitored closely by professionals with a good understanding of health benefits.
  • Informed consent: Consent is a legal term and should be used with respect to specific tasks. A person who is delusional in some but not all areas of life might be adjudicated competent by a court to make medical and financial decisions for him or herself.
  • Incarceration: One of the unintended consequences of deinstitutionalization was an increase in the number of chronically mentally ill persons in jails and prisons in the United States.30
 
Acknowledgments

I am grateful to Drs Lawrence Herz and Jennifer Kymalainen and also to Stephen Proper for their careful reading of this article; all mistakes are my own.



More on Schizophrenia

Overview: Schizophrenia
Differential Diagnoses & Workup: Schizophrenia
Treatment & Medication: Schizophrenia
Follow-up: Schizophrenia
References
Further Reading

References

  1. Wright IC, Rabe-Hesketh S, Woodruff PW, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. Jan 2000;157(1):16-25. [Medline].

  2. Sigmundsson T, Suckling J, Maier M, et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry. Feb 2001;158(2):234-43. [Medline].

  3. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. Jan-Feb 1996;3(5):241-53. [Medline].

  4. Hyde TM, Deep-Soboslay A, Iglesias B, et al. Enuresis as a premorbid developmental marker of schizophrenia. Brain. Sep 2008;131:2489-98. [Medline].

  5. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. Nov 19 1994;344(8934):1398-402. [Medline].

  6. Ho BC, Andreasen NC. Long delays in seeking treatment for schizophrenia. Lancet. Mar 24 2001;357(9260):898-900. [Medline].

  7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Press; 2000.

  8. Kety SS, Wender PH, Jacobsen B, et al. Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Replication of the Copenhagen Study in the rest of Denmark. Arch Gen Psychiatry. Jun 1994;51(6):442-55. [Medline].

  9. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. May 15 2005;57(10):1117-27. [Medline].

  10. Shifman S, Johannesson M, Bronstein M, et al. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet. Feb 2008;4(2):e28. [Medline].

  11. Wratten NS, Memoli H, Huang Y, Dulencin AM, Matteson PG, Cornacchia MA, et al. Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. Am J Psychiatry. April/2009;166:434-41. [Medline].

  12. Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. Aug 2004;61 (8):774-80. [Medline].

  13. Torrey EF, Bowler AE, Rawlings R, Terrazas A. Seasonality of schizophrenia and stillbirths. Schizophr Bull. 1993;19(3):557-62. [Medline].

  14. Cummings JL, Gosenfeld LF, Houlihan JP, McCaffrey T. Neuropsychiatric disturbances associated with idiopathic calcification of the basal ganglia. Biol Psychiatry. May 1983;18(5):591-601. [Medline].

  15. Rosebush PI, MacQueen GM, Clarke JT, et al. Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. J Clin Psychiatry. Aug 1995;56(8):347-53. [Medline].

  16. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. May 1994;51(5):375-82. [Medline].

  17. Reuler JB, Girard DE, Cooney TG. Current concepts. Wernicke's encephalopathy. N Engl J Med. Apr 18 1985;312(16):1035-9. [Medline].

  18. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. Nov 2001;158(11):1774-82. [Medline].

  19. Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry. October/2003;5:205-215. [Medline].

  20. Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet. Apr 1 2000;355(9210):1155-6. [Medline].

  21. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic drugs and venous thromboembolism. Lancet. Jul 15 2000;356(9225):252. [Medline].

  22. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. Suppl 1 2007;68:20-7. [Medline].

  23. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med. Mar 14 1991;324(11):746-54. [Medline].

  24. [Best Evidence] Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. Jan 21 2009;CD000059. [Medline].

  25. Kern RS, Glynn SM, Horan WP, Marder SR. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. Mar 2009;35(2):347-61. [Medline].

  26. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. May 2006;163:790-9. [Medline].

  27. Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord. Sep 1982;4(3):173-93. [Medline].

  28. Fazel S, Langstrom N, Hjern A, Grann M, Lichtenstein P. Schizophrenia, substance abuse, and violent crime. JAMA. May 20 2009;301(19):2016-23. [Medline].

  29. Salokangas RK. Medical problems in schizophrenia patients living in the community (alternative facilities). Curr Opin Psychiatry. Jul/2007;20:402-5. [Medline].

  30. Lamb HR, Bachrach LL. Some perspectives on deinstitutionalization. Psychiatr Serv. Aug 2001;52(8):1039-45. [Medline].

Keywords

schizophrenia, schizophrenia symptoms, schizophrenia test, childhood schizophrenia, schizophrenic, signs of schizophrenia, dementia praecox, auditory hallucinations, impaired information processing, delusions, disorganized speech, disorganized behavior, psychiatric disorders, thought disturbances, distorted thinking, mental illness, psychosis, mental disorder, delusions, depression, mania, manic depressive, major depressive disorder, mood disorder, bipolar disorder

Contributor Information and Disclosures

Author

Frances R Frankenburg, MD, Associate Professor, Department of Psychiatry, Boston University School of Medicine; Chief of Inpatient Psychiatry and Consulting Psychiatrist, Edith Nourse Rogers Memorial Veterans Administration Medical Center; Associate Psychiatrist, McLean Hospital
Frances R Frankenburg, MD is a member of the following medical societies: Alpha Omega Alpha, American Psychiatric Association, and International Society for the Study of Personality Disorders
Disclosure: Nothing to disclose.

Medical Editor

Ronald C Albucher, MD, Chief Medical Officer, Westside Community Services; Consulting Staff, California Pacific Medical Center
Ronald C Albucher, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Eduardo Dunayevich, MD, Adjunct Assistant Professor, Department of Psychiatry, University of Cincinnati; Clinical Research Physician, Neuroscience, Lilly Research Laboratories
Eduardo Dunayevich, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: Nothing to disclose.

CME Editor

Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin
Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association
Disclosure: lilly Honoraria Speaking and teaching; Forest Labs Honoraria Speaking and teaching; AstraZeneca Honoraria Speaking and teaching; Pfizer Grant/research funds Speaking and teaching; Northstar Grant/research funds Research; Novartis Grant/research funds research; Pfizer  Speaking and teaching; Sanofi-avetis Grant/research funds research; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research

Chief Editor

Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA
Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.